Oxidation of CaMKII determines the cardiotoxic effects of aldosterone

B. Julie He, Mei-ling A. Joiner, Madhu V. Singh, Elizabeth D. Luczak, Paari Dominic Swaminathan, Olha M. Koval, William Kutschke, Chantal Allamargot, Jinying Yang, Xiaoqun Guan, Kathy Zimmerman, Isabella M. Grumbach, Robert M. Weiss, Douglas R. Spitz, Curt D. Sigmund, W. Matthijs Blankesteijn, Stephane Heymans, Peter J. Mohler, Mark E. Anderson*

*Corresponding author for this work

Research output: Contribution to journalArticleAcademicpeer-review

163 Citations (Web of Science)
15 Downloads (Pure)

Abstract

Excessive activation of the beta-adrenergic, angiotensin II (Ang II) and aldosterone signaling pathways promotes mortality after myocardial infarction, and antagonists targeting these pathways are core therapies for treating this condition. Catecholamines and Ang II activate the multifunctional Ca(2+)/calmodulin-dependent protein kinase II (CaMKII), the inhibition of which prevents isoproterenol-mediated and Ang II-mediated cardiomyopathy. Here we show that aldosterone exerts direct toxic actions on myocardium by oxidative activation of CaMKII, causing cardiac rupture and increased mortality in mice after myocardial infarction. Aldosterone induces CaMKII oxidation by recruiting NADPH oxidase, and this oxidized and activated CaMKII promotes matrix metalloproteinase 9 (MMP9) expression in cardiomyocytes. Myocardial CaMKII inhibition, overexpression of methionine sulfoxide reductase A (an enzyme that reduces oxidized CaMKII) or NADPH oxidase deficiency prevented aldosterone-enhanced cardiac rupture after myocardial infarction. These findings show that oxidized myocardial CaMKII mediates the cardiotoxic effects of aldosterone on the cardiac matrix and establish CaMKII as a nodal signal for the neurohumoral pathways associated with poor outcomes after myocardial infarction.
Original languageEnglish
Pages (from-to)1610-U125
JournalNature Medicine
Volume17
Issue number12
DOIs
Publication statusPublished - Dec 2011

Cite this